The nonlipid effects of statins on endothelial function

被引：51

作者：

Beckman, Joshua A. ^{[1
]}

Creager, Mark A. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA

来源：

TRENDS IN CARDIOVASCULAR MEDICINE | 2006年 / 16卷 / 05期

关键词：

D O I：

10.1016/j.tcm.2006.03.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hydroxymethylglutaryl-coenzyme A reductase inhibitors or statins constitute one of the wonder drugs of the last 2 decades. Use of this hypolipidemic medication class reduces morbidity and mortality in patients with a wide variety of cholesterol levels. Beneficial effects of the medication are seen in advance of changes in lipids suggesting nonlipid mechanisms may play a role in mediating these benefits of statins. One important nonlipid mechanism by which statins may improve vascular outcomes is restoration of normal endothelial cell function. This review will discuss the nonlipid effects of statins on endothelial cell function to highlight other avenues of benefit conferred by these medications.

引用

页码：156 / 162

页数：7

共 89 条

[41] Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
Laufs, U
LaFata, V
Liao, JK
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (50) : 31725 - 31729
[42] Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
Laufs, U
La Fata, V
Plutzky, J
Liao, JK
[J]. CIRCULATION, 1998, 97 (12) : 1129 - 1135
[43] Isoprenoids as mediators of the biological effects of statins
Liao, JK
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (03) : 285 - 288
[44] Atherosclerosis
Lusis, AJ
[J]. NATURE, 2000, 407 (6801) : 233 - 241
[45] Meta-analysis, clinical trials, and transferability of research results into practice - The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease
Marchioli, R
Marfisi, RM
Carinci, F
Tognoni, G
[J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (11) : 1158 - 1172
[46] Pitavastatin-induced Thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family
Masamura, K
Oida, K
Kanehara, H
Suzuki, J
Horie, S
Ishii, H
Miyamori, I
[J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (03) : 512 - 517
[47] Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions
Mason, RP
Walter, MF
Day, CA
Jacob, RF
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (5A) : 11F - 23F
[48] Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively
Molloy, KJ
Thompson, MM
Schwalbe, EC
Bell, PRF
Naylor, AR
Loftus, IM
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (01) : 144 - 146
[49] MONCADA S, 1993, NEW ENGL J MED, V329, P2002
[50] Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (JUPITER) - Can C-reactive protein be used to target statin therapy in primary prevention?
Mora, S
Ridker, PM
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (2A) : 33A - 41A

← 1 2 3 4 5 6 7 8 9 →